ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group

MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.

ViaDerma licenses products in fields of medicine ranging from infectious disease treatments to stem-cell therapy. Pharmaceutical companies seeking more efficient methods for delivering their products to patients will have new access to solutions worldwide, as The Brewer Group, Inc. and ViaDerma, Inc. leverage TBG's vast network to pave the way for new strategic business alliances and expand the range of the breakthrough rapid delivery of nutrients and medicines using ViaDerma's technology.

ViaDerma continues to develop new applications for its trade-secret Rapid Active Ingredient Delivery System (RAIDS), and founder Dr. Christopher Otiko emphasizes its extreme versatility. "The speed of the RAIDS method for pharmaceutical distribution and the wide variety of products that can utilize it will allow medical professionals and general consumers alike to benefit from faster treatment," Dr. Otiko said. "Products using RAIDS are at the forefront of medical sophistication and nearly any drug that medical professionals can administer as a pill can utilize RAIDS for quicker delivery, from pain relievers to cosmetics. As ViaDerma, Inc. expands, our partnership with The Brewer Group will combine their experience and network with our revolutionary technologies to reach ever-larger audiences."

Using tailored business development strategies including exclusive access to its extensive network and established relationships spanning the globe, TBG will reach out to synergetic companies and partner organizations, explore licensing opportunities as well as provide ongoing marketing support and enhance global exposure for ViaDerma's unique technology.

"I'm excited to be working with an organization like ViaDerma, because their technology represents a fundamental shift in the way we should expect treatment to progress," The Brewer Group CEO H.E. Ambassador Jack Brewer said. "What if patients saw results from antibiotics after just a day of treatment, instead of a week? People would come to demand that kind of speed, and TBG is ready to connect ViaDerma Inc. with strategic partners to meet those expectations."

About ViaDerma, Inc.

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development. ViaDerma licenses products in the fields of medicine ranging from infectious diseases to stem-cell therapy. Dr. Christopher Otiko is the company's founder, and ViaDerma became a publicly-traded company in 2014. For more information, go to www.viadermalicensing.com.

About The Brewer Group, Inc.

The Brewer Group (TBG) is a multi-faceted global investment advisory firm focused on providing tailored services including capital markets, asset management, specialty finance and business development for public and private companies as well as high-profile clientele. TBG leverages its relationships with key international decision-makers spanning government agencies, private equity firms, corporations, NPOs, leaders in government, and sports and entertainment to place TBG in a unique position to execute a wide range of services around the globe. For further information, please visit www.thebrewergroup.com.

SOURCE ViaDerma, Inc.